<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - 获取免费报告) 的股价在周三达到了新的 52 周高点。该股最高交易价格为 41.05 美元，最后交易价格为 40.9750 美元，成交量为 250063 股。该股此前收盘价为 40.97 美元。</p>
<h2>华尔街分析师预测增长</h2>
<ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
<p>APLS 已经成为多份研究分析师报告的主题。Roth Mkm 在 4 月 2 日的研究报告中将 Apellis Pharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。花旗集团在 4 月 1 日的报告中重申了 “中性” 评级，并将 Apellis Pharmaceuticals 的目标价设定为 41.00 美元（下调自 44.00 美元）。Wedbush 在 2 月 25 日的报告中将 Apellis Pharmaceuticals 的目标价从 20.00 美元下调至 18.00 美元，并对该股给予 “中性” 评级。HC Wainwright 在 4 月 1 日的报告中将 Apellis Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”，并将该公司的目标价从 48.00 美元下调至 41.00 美元。最后，Needham &amp; Company LLC 在 3 月 31 日的报告中将 Apellis Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”。三位投资分析师对该股给予 “买入” 评级，十八位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Apellis Pharmaceuticals 的共识评级为 “持有”，共识目标价为 34.89 美元。</p>
<p><strong>查看我们关于 Apellis Pharmaceuticals 的最新报告</strong></p>
<h2>Apellis Pharmaceuticals 股票上涨 0.0%</h2>
<ul>
<li>小型股是否预示市场下跌？</li>
</ul>
<p>该公司的 50 日简单移动平均线为 29.59 美元，200 日简单移动平均线为 25.35 美元。该公司的债务与股本比率为 0.98，流动比率为 3.14，速动比率为 2.70。该公司的市值为 52.5 亿美元，市盈率为 315.29，贝塔值为-0.24。</p>
<p>Apellis Pharmaceuticals (NASDAQ:APLS - 获取免费报告) 最近于 2 月 24 日发布了季度财报。该公司报告每股收益（EPS）为 0.47 美元，超出市场共识预期的（-0.39 美元）0.86 美元。Apellis Pharmaceuticals 的净利润率为 2.23%，股本回报率为 8.20%。该公司本季度的收入为 1.9991 亿美元，而分析师预期为 1.9928 亿美元。在去年同期，该公司每股收益为（-0.29 美元）。该公司的季度收入同比下降了 5.9%。分析师平均预测 Apellis Pharmaceuticals, Inc.在本年度将发布-1.23 的每股收益。</p>
<h2>机构投资者对 Apellis Pharmaceuticals 的看法</h2>
<p>大型投资者最近对该股的持仓进行了调整。SG Americas Securities LLC 在第四季度将其在 Apellis Pharmaceuticals 的持仓增加了 35.9%。SG Americas Securities LLC 现在拥有 567,046 股该公司的股票，价值 14,244,000 美元，在上个季度购买了 149,654 股。EFG Asset Management North America Corp.在第三季度将其在 Apellis Pharmaceuticals 的持仓增加了 48.0%。EFG Asset Management North America Corp.现在拥有 155,399 股该公司的股票，价值 3,517,000 美元，在上个季度购买了 50,375 股。HighVista Strategies LLC 在第三季度将其在 Apellis Pharmaceuticals 的持仓增加了 68.2%。HighVista Strategies LLC 现在拥有 145,729 股该公司的股票，价值 3,298,000 美元，在上个季度购买了 59,066 股。Readystate Asset Management LP 在第三季度购买了 Apellis Pharmaceuticals 的新股份，价值 5,476,000 美元。最后，诺瓦斯科舍银行在第三季度将其在 Apellis Pharmaceuticals 的持仓增加了 144.8%。诺瓦斯科舍银行现在拥有 1,456,225 股该公司的股票，价值 32,954,000 美元，在上个季度购买了 861,413 股。96.29% 的股票由对冲基金和其他机构投资者持有。</p>
<h2>Apellis Pharmaceuticals 公司简介</h2>
<p>(获取免费报告)</p>
<p>Apellis Pharmaceuticals, Inc.，在 NASDAQ 交易，股票代码为 APLS，是一家临床阶段的生物制药公司，专注于开发针对补体级联反应的新疗法，以治疗罕见且严重的疾病。该公司的研发工作集中在调节补体蛋白，以应对一系列眼科、血液和肾脏疾病。Apellis 利用其专有的 compstatin 技术平台设计针对性抑制剂，旨在改善患者的治疗效果和生活质量。</p>
<p>该公司的主要上市产品 Syfovre（pegcetacoplan）是一种用于治疗与年龄相关的黄斑变性引起的地理萎缩的玻璃体内补体 C3 抑制剂，并正在对其他视网膜疾病进行持续研究。</p>
<h2>另见</h2>
<ul>
<li>五只我们更看好的股票，胜过 Apellis Pharmaceuticals</li>
</ul>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1000 美元在 Apellis Pharmaceuticals 吗？</h2>
<p>在你考虑投资 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Apellis Pharmaceuticals 并不在名单上。</p>
<p>虽然 Apellis Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

APLS

2 倍做多纳斯达克生物技术 ETF - ProShares

医药突破 ETF - ALPS

<p>Apellis Pharmaceuticals（纳斯达克代码：APLS）创下了 52 周新高，达到 41.05 美元，收盘价为 40.9750 美元，交易量为 250,063 股。分析师的评级意见不一，其中三位给予买入评级，十八位给予持有评级，二位给予卖出评级。该公司报告每股收益为 0.47 美元，超出预期，但收入同比下降了 5.9%。机构投资者持有 96.29% 的股份，Apellis 专注于罕见疾病的治疗，其主要产品 Syfovre 已获批准用于治疗地理性萎缩</p>

<p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - Get Free Report)'s share price reached a new 52-week high on Wednesday . The stock traded as high as $41.05 and last traded at $40.9750, with a volume of 250063 shares trading hands. The stock had previously closed at $40.97.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc. (NASDAQ:APLS - 获取免费报告) 的股价在周三达到了新的 52 周高点。该股最高交易价格为 41.05 美元，最后交易价格为 40.9750 美元，成交量为 250063 股。该股此前收盘价为 40.97 美元。</p>
</div><h2>Wall Street Analysts Forecast Growth</h2>
<div class="lb-trans"><h2>华尔街分析师预测增长</h2>
</div><ul>
<li>Beam Therapeutics Bolts Higher on Gene Therapy Licensing Payments</li>
</ul>
<div class="lb-trans"><ul>
<li>Beam Therapeutics 因基因治疗许可支付而大幅上涨</li>
</ul>
</div><p>APLS has been the subject of several research analyst reports. Roth Mkm downgraded shares of Apellis Pharmaceuticals from a &#34;strong-buy&#34; rating to a &#34;hold&#34; rating in a research note on Thursday, April 2nd. Citigroup reissued a &#34;neutral&#34; rating and set a $41.00 price objective (down from $44.00) on shares of Apellis Pharmaceuticals in a report on Wednesday, April 1st. Wedbush cut their price objective on shares of Apellis Pharmaceuticals from $20.00 to $18.00 and set a &#34;neutral&#34; rating on the stock in a report on Wednesday, February 25th. HC Wainwright lowered shares of Apellis Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating and cut their price objective for the company from $48.00 to $41.00 in a report on Wednesday, April 1st. Finally, Needham &amp; Company LLC lowered shares of Apellis Pharmaceuticals from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Tuesday, March 31st. Three investment analysts have rated the stock with a Buy rating, eighteen have assigned a Hold rating and two have given a Sell rating to the company's stock. According to MarketBeat, Apellis Pharmaceuticals has a consensus rating of &#34;Hold&#34; and a consensus price target of $34.89.</p>
<div class="lb-trans"><p>APLS 已经成为多份研究分析师报告的主题。Roth Mkm 在 4 月 2 日的研究报告中将 Apellis Pharmaceuticals 的股票评级从 “强力买入” 下调至 “持有”。花旗集团在 4 月 1 日的报告中重申了 “中性” 评级，并将 Apellis Pharmaceuticals 的目标价设定为 41.00 美元（下调自 44.00 美元）。Wedbush 在 2 月 25 日的报告中将 Apellis Pharmaceuticals 的目标价从 20.00 美元下调至 18.00 美元，并对该股给予 “中性” 评级。HC Wainwright 在 4 月 1 日的报告中将 Apellis Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”，并将该公司的目标价从 48.00 美元下调至 41.00 美元。最后，Needham &amp; Company LLC 在 3 月 31 日的报告中将 Apellis Pharmaceuticals 的股票评级从 “买入” 下调至 “持有”。三位投资分析师对该股给予 “买入” 评级，十八位分析师给予 “持有” 评级，两位分析师给予 “卖出” 评级。根据 MarketBeat 的数据，Apellis Pharmaceuticals 的共识评级为 “持有”，共识目标价为 34.89 美元。</p>
</div><p><strong>Check Out Our Latest Report on Apellis Pharmaceuticals</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Apellis Pharmaceuticals 的最新报告</strong></p>
</div><h2>Apellis Pharmaceuticals Stock Up 0.0%</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 股票上涨 0.0%</h2>
</div><ul>
<li>Are Small Caps a Harbinger of Market Declines?</li>
</ul>
<div class="lb-trans"><ul>
<li>小型股是否预示市场下跌？</li>
</ul>
</div><p>The company's fifty day simple moving average is $29.59 and its 200-day simple moving average is $25.35. The company has a debt-to-equity ratio of 0.98, a current ratio of 3.14 and a quick ratio of 2.70. The firm has a market capitalization of $5.25 billion, a PE ratio of 315.29 and a beta of -0.24.</p>
<div class="lb-trans"><p>该公司的 50 日简单移动平均线为 29.59 美元，200 日简单移动平均线为 25.35 美元。该公司的债务与股本比率为 0.98，流动比率为 3.14，速动比率为 2.70。该公司的市值为 52.5 亿美元，市盈率为 315.29，贝塔值为-0.24。</p>
</div><p>Apellis Pharmaceuticals (NASDAQ:APLS - Get Free Report) last released its quarterly earnings results on Tuesday, February 24th. The company reported $0.47 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.39) by $0.86. Apellis Pharmaceuticals had a net margin of 2.23% and a return on equity of 8.20%. The business had revenue of $199.91 million for the quarter, compared to analyst estimates of $199.28 million. During the same period in the previous year, the company earned ($0.29) earnings per share. The business's revenue for the quarter was down 5.9% on a year-over-year basis. On average, analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.23 EPS for the current year.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals (NASDAQ:APLS - 获取免费报告) 最近于 2 月 24 日发布了季度财报。该公司报告每股收益（EPS）为 0.47 美元，超出市场共识预期的（-0.39 美元）0.86 美元。Apellis Pharmaceuticals 的净利润率为 2.23%，股本回报率为 8.20%。该公司本季度的收入为 1.9991 亿美元，而分析师预期为 1.9928 亿美元。在去年同期，该公司每股收益为（-0.29 美元）。该公司的季度收入同比下降了 5.9%。分析师平均预测 Apellis Pharmaceuticals, Inc.在本年度将发布-1.23 的每股收益。</p>
</div><h2>Institutional Investors Weigh In On Apellis Pharmaceuticals</h2>
<div class="lb-trans"><h2>机构投资者对 Apellis Pharmaceuticals 的看法</h2>
</div><p>Large investors have recently made changes to their positions in the stock. SG Americas Securities LLC grew its holdings in shares of Apellis Pharmaceuticals by 35.9% during the fourth quarter. SG Americas Securities LLC now owns 567,046 shares of the company's stock valued at $14,244,000 after buying an additional 149,654 shares during the last quarter. EFG Asset Management North America Corp. grew its holdings in shares of Apellis Pharmaceuticals by 48.0% during the third quarter. EFG Asset Management North America Corp. now owns 155,399 shares of the company's stock valued at $3,517,000 after buying an additional 50,375 shares during the last quarter. HighVista Strategies LLC grew its holdings in shares of Apellis Pharmaceuticals by 68.2% during the third quarter. HighVista Strategies LLC now owns 145,729 shares of the company's stock valued at $3,298,000 after buying an additional 59,066 shares during the last quarter. Readystate Asset Management LP purchased a new stake in shares of Apellis Pharmaceuticals during the third quarter valued at $5,476,000. Finally, Bank of Nova Scotia grew its holdings in shares of Apellis Pharmaceuticals by 144.8% during the third quarter. Bank of Nova Scotia now owns 1,456,225 shares of the company's stock valued at $32,954,000 after buying an additional 861,413 shares during the last quarter. 96.29% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>大型投资者最近对该股的持仓进行了调整。SG Americas Securities LLC 在第四季度将其在 Apellis Pharmaceuticals 的持仓增加了 35.9%。SG Americas Securities LLC 现在拥有 567,046 股该公司的股票，价值 14,244,000 美元，在上个季度购买了 149,654 股。EFG Asset Management North America Corp.在第三季度将其在 Apellis Pharmaceuticals 的持仓增加了 48.0%。EFG Asset Management North America Corp.现在拥有 155,399 股该公司的股票，价值 3,517,000 美元，在上个季度购买了 50,375 股。HighVista Strategies LLC 在第三季度将其在 Apellis Pharmaceuticals 的持仓增加了 68.2%。HighVista Strategies LLC 现在拥有 145,729 股该公司的股票，价值 3,298,000 美元，在上个季度购买了 59,066 股。Readystate Asset Management LP 在第三季度购买了 Apellis Pharmaceuticals 的新股份，价值 5,476,000 美元。最后，诺瓦斯科舍银行在第三季度将其在 Apellis Pharmaceuticals 的持仓增加了 144.8%。诺瓦斯科舍银行现在拥有 1,456,225 股该公司的股票，价值 32,954,000 美元，在上个季度购买了 861,413 股。96.29% 的股票由对冲基金和其他机构投资者持有。</p>
</div><h2>Apellis Pharmaceuticals Company Profile</h2>
<div class="lb-trans"><h2>Apellis Pharmaceuticals 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(获取免费报告)</p>
</div><p>Apellis Pharmaceuticals, Inc, traded as NASDAQ:APLS, is a clinical-stage biopharmaceutical company focused on the development of novel therapies targeting the complement cascade for the treatment of rare and debilitating diseases. The company's research and development efforts center on modulating complement proteins to address a range of ophthalmologic, hematologic and renal conditions. Apellis leverages its proprietary compstatin technology platform to design targeted inhibitors intended to improve patient outcomes and quality of life.</p>
<div class="lb-trans"><p>Apellis Pharmaceuticals, Inc.，在 NASDAQ 交易，股票代码为 APLS，是一家临床阶段的生物制药公司，专注于开发针对补体级联反应的新疗法，以治疗罕见且严重的疾病。该公司的研发工作集中在调节补体蛋白，以应对一系列眼科、血液和肾脏疾病。Apellis 利用其专有的 compstatin 技术平台设计针对性抑制剂，旨在改善患者的治疗效果和生活质量。</p>
</div><p>The company's lead marketed product, Syfovre (pegcetacoplan), is an intravitreal complement C3 inhibitor approved for geographic atrophy secondary to age-related macular degeneration, with ongoing investigations in other retinal disorders.</p>
<div class="lb-trans"><p>该公司的主要上市产品 Syfovre（pegcetacoplan）是一种用于治疗与年龄相关的黄斑变性引起的地理萎缩的玻璃体内补体 C3 抑制剂，并正在对其他视网膜疾病进行持续研究。</p>
</div><h2>See Also</h2>
<div class="lb-trans"><h2>另见</h2>
</div><ul>
<li>Five stocks we like better than Apellis Pharmaceuticals</li>
</ul>
<div class="lb-trans"><ul>
<li>五只我们更看好的股票，胜过 Apellis Pharmaceuticals</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Apellis Pharmaceuticals Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在 Apellis Pharmaceuticals 吗？</h2>
</div><p>Before you consider Apellis Pharmaceuticals, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑投资 Apellis Pharmaceuticals 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Apellis Pharmaceuticals wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐的股票。MarketBeat 已识别出五只顶级分析师正在悄悄向客户推荐的股票，以便在更广泛的市场注意到之前购买……而 Apellis Pharmaceuticals 并不在名单上。</p>
</div><p>While Apellis Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Apellis Pharmaceuticals 目前在分析师中被评为持有评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Apellis Pharmaceuticals (NASDAQ:APLS) Reaches New 52-Week High  - Here's What Happened

Market Beat

Apellis Pharma

基因改革 ETF - ARK

医疗业 ETF - SPDR

生物科技 ETF - VanEck Vectors

医疗业 ETF - Vanguard

动态生物技术与基因组 ETF - Invesco

Invesco Nasdaq Biotechnology ETF

纽交所高增长板生物技术指数 ETF - First Trust

纳斯达克生物科技指数 ETF - iShares Nasdaq

标普生物技术 ETF - SPDR

美国制药 ETF - iShares

标普生物技术 3 倍做多 - Direxion

Beam Therapeutics

花旗

Bank of Nova Scottia

CITIGROUP INC 6.250 NON CUM SER II PFD WI

Apellis Pharmaceuticals（纳斯达克代码：APLS）创下新的 52 周高点 - 事情经过如下